O’Melveny & Myers LLP represented Progenics Pharmaceuticals Inc. (Nasdaq: PGNX) in its acquisition of Molecular Insight Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company focused on critical unmet diagnostic and therapeutic needs of the prostate cancer patient.
The O’Melveny team was led by partner Jennifer DePalma, counsel Stanton Lovenworth, and associate Ruchun Ji.
